Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients (NCT07583251)
Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Who can join: Review the eligibility criteria below.
Location: UPMC Presbyterian Hospital — Pittsburgh, Pennsylvania
Age range: 55 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- UPMC Presbyterian Hospital — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (412) 699-9561
Email: mandalpk@pitt.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mild Cognitive Impairment (MCI)
- Wearable Sensor for Early Detection and Monitoring of Cognitive Decline — Los Angeles, California
- Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers — La Jolla, California
- AI-CONECT: A Conversational AI for Early Dementia Prevention in Socially-Isolated Older Adults — Boston, Massachusetts
- Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity — Augusta, Georgia
- An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) — Saint Paul, Minnesota
- Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device. — Palisades Park, New Jersey
Explore by condition: All Mild Cognitive Impairment (MCI) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.